Stockreport

DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report
PDF MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its [Read more]